A phase I trial of MK-2206 in children with refractory malignancies: A Children's Oncology Group study

Maryam Fouladi, John P. Perentesis, Christine L. Phillips, Sarah Leary, Joel M. Reid, Renee M. Mcgovern, Ashish M. Ingle, Charlotte H. Ahern, Matthew M. Ames, Peter Houghton, L. Austin Doyle, Brenda Weigel, Susan M. Blaney

Research output: Contribution to journalArticlepeer-review

30 Scopus citations


Background: We report results of a phase I trial designed to estimate the maximum tolerated dose (MTD), describe dose-limiting toxicities (DLT), and characterize the pharmacokinetic profile of MK-2206, an AKT inhibitor, in children with refractory or recurrent malignancies. Procedure: MK-2206 was administered either every other day (Schedule 1), or once a week (Schedule 2) in a 28-day cycle. Dose escalations in increments of ~30% were independently made in each part using the rolling-six design. Serial pharmacokinetic (PK) studies were obtained. Biological studies include analysis of PI3K/PTEN/AKT-cell signaling pathway in pre and post-therapy in PBMC and in tumors at diagnosis or recurrence. Results: Fifty patients (26 males, median age 12.6 years [range, 3.1-21.9]) with malignant glioma (16), ependymoma (4), hepatocellular carcinoma (3), gliomatosis cereberi (2), or other tumors (22) were enrolled; 40 were fully evaluable for toxicity (Schedule 1, n=23; Schedule 2, n=17). Schedule 1 DLTs included: grade 3 dehydration in 1/6 patients at 28mg/m2; grade 4 hyperglycemia and neutropenia in 1/6 patients at 45mg/m2; and grade 3 rash in 3/6 patients at dose level 4 (58mg/m2). Schedule 2 DLTs included: grade 3 alkaline phosphatase in 1/6 patients at 90mg/m2; grade 3 rash in 1/6 patients at 120mg/m2; and grade 3 rash in 2/6 patients at 155mg/m2. Conclusions: The recommended pediatric phase 2 dose of MK-2206 is 45mg/m2/dose every other day or 120mg/m2/dose weekly. PK appeared linear over the dose range studied. Pediatr Blood Cancer 2014;61:1246-1251.

Original languageEnglish (US)
Pages (from-to)1246-1251
Number of pages6
JournalPediatric Blood and Cancer
Issue number7
StatePublished - Jul 2014


  • AKT inhibitor
  • MK-2206
  • Pediatric
  • Phase I trial
  • Relapsed solid tumors

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology


Dive into the research topics of 'A phase I trial of MK-2206 in children with refractory malignancies: A Children's Oncology Group study'. Together they form a unique fingerprint.

Cite this